A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
CE-224535 is a new medication being developed as an analgesic and anti-inflammatory agent for
the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is
to evaluate the analgesic and anti inflammatory efficacy and safety of CE 224,535 versus
placebo and naproxen treatment in patients with OA knee pain.